Core Insights - Editas Medicine is on track to declare two in vivo editing development candidates by mid-2025, one targeting hematopoietic stem cells (HSCs) and the other targeting liver cells [1][2] - The company has demonstrated preclinical proof of concept in non-human primates and humanized mice, showcasing the potential of its gene upregulation strategy across multiple tissues [3][6] - Editas maintains a strong cash position, with cash, cash equivalents, and marketable securities amounting to $269.9 million as of December 31, 2024, which is expected to fund operations into the second quarter of 2027 [4][17] Business Updates - The company achieved in vivo preclinical proof of concept ahead of schedule, indicating significant progress in its gene editing platform [2] - Editas plans to present further preclinical data for HSCs and liver indications by year-end 2025 [1][6] - The company is also on track to establish an additional target cell type or tissue by the end of 2025 [1][6] Financial Performance - For Q4 2024, Editas reported a net loss of $45.4 million, or $0.55 per share, compared to a net loss of $18.9 million, or $0.23 per share, in Q4 2023 [6][14] - Collaboration and other research and development revenues decreased to $30.6 million in Q4 2024 from $60.0 million in Q4 2023, primarily due to revenue recognized from a license agreement with Vertex Pharmaceuticals [6][14] - For the full year 2024, the net loss attributable to common stockholders was $237.1 million, or $2.88 per share, compared to a net loss of $153.2 million, or $2.02 per share, in 2023 [14][15] Restructuring and Cost Management - The company ended the development of its reni-cel program, leading to a workforce reduction of approximately 65% and restructuring charges of $12.2 million in Q4 2024 [6][7] - Research and development expenses decreased to $48.6 million in Q4 2024 from $69.6 million in Q4 2023, primarily due to reduced costs associated with the reni-cel program [6][14] Upcoming Events - Editas Medicine plans to participate in investor events, including the Leerink Partners Global Biopharma Conference and the Barclays 27th Annual Global Healthcare Conference in March 2024 [9]

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Edward Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Mani Foroohar - Leerink Partners Maury Raycroft - Jefferies Lisa Walter ...

Verve Therapeutics (VERV) Conference February 05, 2025 09:00 AM ET Company Participants Sekar Kathiresan - Co-Founder, CEO & Director Operator Well, good morning, everybody. Thanks for joining us here at Guggenheim's SMIDCAP biotech conference. We sort of target companies below the kind of $12,000,000,000 threshold for this conference because these tend to be the companies that actually have the highest returns, in biotech overall. So it's a great opportunity to be joined here this morning by Verve Therapeu ...

Maravai LifeSciences (MRVI) FY 2023 Conference November 16, 2023 09:00 AM ET Speaker0 Good afternoon. Thanks for being here at the last session of our London conference. We're very excited to have Maribai Life Sciences with us today here to tell us more about the story before we jump into some Q and A, CEO, Trey Martin as well as CFO, Kevin Hurti. Turn it over to Trey. Speaker1 All right. Thank you. Thanks for being here in person. I know it sounds like we're at the tail end of this conference. And also tha ...